Vimian Group AB (publ) VIMIAN
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold; consider adding 10-20% after Q1 confirmation.
Core animal health operations and cash flow development look robust, while the MedTech turnaround and management stability still require confirmation.
Sentiment has improved to weakly positive after the Q2 beat and clearer management announcements, but the market remains watchful on execution (especially MedTech/USA) and acquisition integration risk.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 18 Aug 2026 — The July 17 report showed double-digit growth and MedTech margin gains, driven by organic expansion and LTIP exercises.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Vimian Group AB (publ) is a global animal health group operating across Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company grows through organic initiatives and acquisitions, but near-term uncertainty is elevated due to MedTech weakness and ongoing management changes.
Bull case
Continued double-digit organic growth and stable EBITA margin, with clear improvement in MedTech, can support a higher valuation if cash flow normalizes.
Bear case
Weak cash flow conversion and rising working capital combined with higher net debt may increase focus on the balance sheet and limit upside despite good earnings growth.
Why this signal
Core animal health operations and cash flow development look robust, while the MedTech turnaround and management stability still require confirmation.
Recent news
Major shareholder Fidelio Capital has bought shares worth over 300 MSEK. Handelsbanken has named Vimian a sector favorite. New heads of M&A and Specialty Pharma take office in October. The Q3 report is published on 22 October.